Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction.
We have shown previously that the plecomacrolide antibiotics bafilomycin A1 and B1 significantly attenuate cerebellar granule neuron death resulting from agents that disrupt lysosome function. To further characterize bafilomycin-mediated cytoprotection, we examined its ability to attenuate the death of naïve and differentiated neuronal SH-SY5Y human neuroblastoma cells from agents that induce lysosome dysfunction in vitro, and from in vivo dopaminergic neuron death in C. elegans. Low-dose bafilomycin significantly attenuated SH-SY5Y cell death resulting from treatment with chloroquine, hydroxychloroquine amodiaquine and staurosporine. Bafilomycin also attenuated the chloroquine-induced reduction in processing of cathepsin D, the principal lysosomal aspartic acid protease, to its mature 'active' form. Chloroquine induced autophagic vacuole accumulation and inhibited autophagic flux, effects that were attenuated upon treatment with bafilomycin and were associated with a significant decrease in chloroquine-induced accumulation of detergent-insoluble alpha-synuclein oligomers. In addition, bafilomycin significantly and dose-dependently attenuated dopaminergic neuron death in C. elegans resulting from in vivo over-expression of human wild-type alpha-synuclein. Together, our findings suggest that low-dose bafilomycin is cytoprotective in part through its maintenance of the autophagy-lysosome pathway, and underscores its therapeutic potential for treating Parkinson's disease and other neurodegenerative diseases that exhibit disruption of protein degradation pathways and accumulation of toxic protein species.
Department of Pathology, Neuropathology Division, University of Alabama, Birmingham, AL, USA.
Violetta N
VN
Pivtoraiko
Adam J
AJ
Harrington
Burton J
BJ
Mader
Austin M
AM
Luker
Guy A
GA
Caldwell
Kim A
KA
Caldwell
Kevin A
KA
Roth
John J
JJ
Shacka
D000818:Animals; D001343:Autophagy / Q000187:drug effects* / Q000502:physiology; D017173:Caenorhabditis elegans / Q000187:drug effects; D045744:Cell Line, Tumor; D019610:Cytoprotection / Q000187:drug effects* / Q000502:physiology; D018450:Disease Progression; D006801:Humans; D008247:Lysosomes / Q000187:drug effects* / Q000502:physiology; D018942:Macrolides / Q000494:pharmacology*; D009410:Nerve Degeneration / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
D018942:Macrolides; C057620:bafilomycin A